What F-star Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Brady Todd C | Director | Mar 08 | Tender Offer · U | −15,004 | $7.12 | −$107K | 0 |
| Forster Eliot | PRESIDENT AND CEO | Mar 08 | Disposition to Issuer · D | −73,959 | $7.12 | −$527K | 0 |
| Forster Eliot | PRESIDENT AND CEO | Mar 08 | Tender Offer · U | −347,578 | $7.12 | −$2.47M | 73,959 |
| Bermingham Nessan | Director | Mar 08 | Disposition to Issuer · D | −6,328 | $7.12 | −$45.1K | 0 |
| Bermingham Nessan | Director | Mar 08 | Tender Offer · U | −97,547 | $7.12 | −$695K | 6,328 |
| Deptula-hicks Darlene M | See Remarks | Mar 08 | Disposition to Issuer · D | −25,539 | $7.12 | −$182K | 0 |
| Deptula-hicks Darlene M | See Remarks | Mar 08 | Tender Offer · U | −30,898 | $7.12 | −$220K | 25,539 |
| Race Geoffrey | Director | Mar 08 | Tender Offer · U | −3,937 | $7.12 | −$28K | 0 |
| Arkowitz David | Director | Mar 08 | Tender Offer · U | −8,386 | $7.12 | −$59.7K | 0 |
| Benz Edward Jr | Director | Mar 08 | Disposition to Issuer · D | −4,385 | $7.12 | −$31.2K | 0 |
| Kayitalire Louis | CHIEF MEDICAL OFFICER | Mar 08 | Disposition to Issuer · D | −25,019 | $7.12 | −$178K | 0 |
| Kayitalire Louis | CHIEF MEDICAL OFFICER | Mar 08 | Tender Offer · U | −29,236 | $7.12 | −$208K | 25,019 |
| Brewis Neil | CHIEF SCIENTIFIC OFFICER | Mar 08 | Disposition to Issuer · D | −9,375 | $7.12 | −$66.8K | 0 |
| Brewis Neil | CHIEF SCIENTIFIC OFFICER | Mar 08 | Tender Offer · U | −105,088 | $7.12 | −$748K | 9,375 |
| Forster Eliot | President and CEO | Jul 29 | Exercise / conversion · M | +260,977 | $0.11 | +$28.7K | 421,537 |
| Race Geoffrey | Director | Jul 29 | Exercise / conversion · M | +3,937 | $0.11 | +$433 | 3,937 |
| Brewis Neil | Chief Scientific Officer | Jul 29 | Exercise / conversion · M | +76,619 | $0.11 | +$8.43K | 114,463 |
| Kayitalire Louis | Chief Medical Officer | Nov 02 | Disclosed 10b5-1 sale · S | −25 | $6.85 | −$171 | 54,255 |
| Kayitalire Louis | Chief Medical Officer | Nov 02 | Disclosed 10b5-1 sale · S | −39 | $6.81 | −$266 | 54,280 |
| Kayitalire Louis | Chief Medical Officer | Oct 04 | Disclosed 10b5-1 sale · S | −64 | $7.23 | −$462 | 54,319 |
Loading...